2026 – IP Group Australia

2022 data tab

Date	Title
15 May 2026	Atisama Therapeutics advances RB042 into multiple ascending dose cohorts of Phase 1 Trial and appoints Bernard Coulie as Chair of the Board
15 May 2026	Rage Bio becomes Atisama Therapeutics
30 Mar 2026	IP Group Australia and CEFC launch the Climate Catalyst Fund
13 Mar 2026	IP Group backs MGA Thermal’s technology to accelerate heavy industry decarbonisation
27 Feb 2026	IP Group ANZ startup receives $5m boost for critical energy mineral processing

News 0